Peiyi Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peiyi Ye has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Yaozhong Kong
Department of Nephrology, the First People’s Hospital of Foshan, China (C.X., Y.K.).
2 shared publications Chao Xie
Nephrology Department, The First People’s Hospital of Foshan, Foshan, China
1 shared publication- Chao Xie
Department of Nephrology, the First People’s Hospital of Foshan, Foshan, Guangdong, China
1 shared publication Chuling Zhang
Clinical Research Institute, The First People’s Hospital of Foshan, Foshan, China
1 shared publicationHuishi Li
Nephrology Department, The First People’s Hospital of Foshan, Foshan, China
1 shared publicationLifang Zhang
Clinical Research Institute, The First People’s Hospital of Foshan, Foshan, China
1 shared publication
Latest Publications
- Open Access
- 13 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (24) , e42820
A case report and literature review on new-onset systemic lupus erythematosus leading to thrombocytopenia in a hemodialysis patient
Rationale: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects various organs. Disease activity in SLE may diminish following the initiation of dialysis in patients with end-stage renal disease. Patient concern: We report the case of a 69-year-old female patient with a prior diagnosis of IgA nephropathy who developed SLE characterized by severe thrombocytopenia after hemodialysis. Diagnoses: The patient presented with fever, rash, polyarthralgia, thrombocytopenia, hemolytic anemia, positive antinuclear antibodies, anti-nucleosome antibodies, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies, and decreased complement C3 and C4 levels. She was diagnosed with SLE complicated by hematological damage and immune thrombocytopenia. Interventions: The treatment included an intravenous infusion of 5% human immunoglobulin at 20 g/day for 5 days combined with an intravenous infusion of methylprednisolone at 500 mg/day for 3 days. Plasma exchange therapy was conducted a total of 3 times. Outcomes: The patient was discharged with methylprednisolone and hydroxychloroquine treatment. The platelet count was stable, antinuclear antibody, anti-nucleosome antibody, antiphospholipid antibody, Coombs test, and complement C3 and C4 levels were normal after discharge. Lessons: In patients with unexplained thrombocytopenia, the possibility of SLE should be considered even after hemodialysis initiation.
- 13 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (24) , e42820
Open AccessA case report and literature review on new-onset systemic lupus erythematosus leading to thrombocytopenia in a hemodialysis patient
Rationale: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects various organs. Disease activity in SLE may diminish following the initiation of dialysis in patients with end-stage renal disease. Patient concern: We report the case of a 69-year-old female patient with a prior diagnosis of IgA nephropathy who developed SLE characterized by severe thrombocytopenia after hemodialysis. Diagnoses: The patient presented with fever, rash, polyarthralgia, thrombocytopenia, hemolytic anemia, positive antinuclear antibodies, anti-nucleosome antibodies, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies, and decreased complement C3 and C4 levels. She was diagnosed with SLE complicated by hematological damage and immune thrombocytopenia. Interventions: The treatment included an intravenous infusion of 5% human immunoglobulin at 20 g/day for 5 days combined with an intravenous infusion of methylprednisolone at 500 mg/day for 3 days. Plasma exchange therapy was conducted a total of 3 times. Outcomes: The patient was discharged with methylprednisolone and hydroxychloroquine treatment. The platelet count was stable, antinuclear antibody, anti-nucleosome antibody, antiphospholipid antibody, Coombs test, and complement C3 and C4 levels were normal after discharge. Lessons: In patients with unexplained thrombocytopenia, the possibility of SLE should be considered even after hemodialysis initiation.
- Open Access
- 27 May 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
The Diagnostic and Prognostic Potential of the B-Cell Repertoire in Membranous Nephropathy
Membranous nephropathy (MN), an autoimmune glomerular disease, is one of the most common causes of nephrotic syndrome in adults. In current clinical practice, the diagnosis is dependent on renal tissue biopsy. A new method for diagnosis and prognosis surveillance is urgently needed for patients. In the present study, we recruited 66 MN patients before any treatment and 11 healthy control (HC) and analyzed multiple aspects of the immunoglobulin heavy chain (IGH) repertoire of these samples using high-throughput sequencing. We found that the abnormalities of CDR-H3 length, hydrophobicity, somatic hypermutation (SHM), and germ line index were progressively more prominent in patients with MN, and the frequency of IGHV3-66 in post-therapy patients was significantly lower than that in pre-therapy patients. Moreover, we found that the IGHV3-38 gene was significantly related to PLA2R, which is the most commonly used biomarker. The most important discovery was that several IGHV, IGHD transcripts, CDR-H3 length, and SHM rate in pre-therapy patients had the potential to predict the therapeutic effect. Our study further demonstrated that the IGH repertoire could be a potential biomarker for prognosis prediction of MN. The landscape of circulating B-lymphocyte repertoires sheds new light on the detection and surveillance of MN.
- 27 May 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Open AccessThe Diagnostic and Prognostic Potential of the B-Cell Repertoire in Membranous Nephropathy
Membranous nephropathy (MN), an autoimmune glomerular disease, is one of the most common causes of nephrotic syndrome in adults. In current clinical practice, the diagnosis is dependent on renal tissue biopsy. A new method for diagnosis and prognosis surveillance is urgently needed for patients. In the present study, we recruited 66 MN patients before any treatment and 11 healthy control (HC) and analyzed multiple aspects of the immunoglobulin heavy chain (IGH) repertoire of these samples using high-throughput sequencing. We found that the abnormalities of CDR-H3 length, hydrophobicity, somatic hypermutation (SHM), and germ line index were progressively more prominent in patients with MN, and the frequency of IGHV3-66 in post-therapy patients was significantly lower than that in pre-therapy patients. Moreover, we found that the IGHV3-38 gene was significantly related to PLA2R, which is the most commonly used biomarker. The most important discovery was that several IGHV, IGHD transcripts, CDR-H3 length, and SHM rate in pre-therapy patients had the potential to predict the therapeutic effect. Our study further demonstrated that the IGH repertoire could be a potential biomarker for prognosis prediction of MN. The landscape of circulating B-lymphocyte repertoires sheds new light on the detection and surveillance of MN.